Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

Summary

This study will test the effectiveness and safety of Venetoclax in combination with standard induction regimen for patients with acute leukemia and poor prognosis.

Timeline

Start

2018-10-26

Primary completion

2025-07-21

Completion

2026-07-15

Publications

• Marconi G, Piciocchi A, Audisio E, Papayannidis C, Cerrano M, Minotti C, Paoloni F, Guolo F, Bocchia M, Rondoni M, Lico A, Carrabba MG, Della Porta MG, Frigeni M, Giaccone L, Beltrami G, Cattaneo C, Di Chio MC, Serio B, Crea E, Freilone R, Capria S, Curti A, Minetto P, la Sala E, Nanni J, Zannetti BA, Simonetti G, Bochicchio MT, Saglio G, Lemoli RM, Venditti A, Vignetti M, Fazi P, Martinelli G. Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML. Blood Adv. 2025 May 27;9(10):2542-2552. doi: 10.1182/bloodadvances.2024014901.

Drugs

Indications